Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662857 · ClinicalTrials.gov registry record · Phase 2
A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro
A Phase 2 study of Diabetes Mellitus, Type 1, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 2
- Study locations
NCT00662857 is a Phase 2 study of Diabetes Mellitus, Type 1 that has completed, run by Mannkind Corporation. The registered enrollment target is 29 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00662857, a Phase 2 study of Diabetes Mellitus, Type 1, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 2
- Study locations
Study Summary
28 subjects to be enrolled for a screening period, 3 dosing visits \& a follow-up visit. Visits 2 and 3 dosing of TI Inhalation Powder, cross over between two 15 U cartridges and one 30 U cartridge. Visit 4 dosing will be a sc injection of 10 IU of RAA (rapid-acting insulin analogue).
Conditions Studied
Interventions
- DRUG Technosphere® Insulin Inhalation Powder
- DRUG Technosphere Insulin® Inhalation Powder
- DRUG RAA Population
Study Locations (2)
California
- Profil Institute for Clinical Research Inc. - Chula Vista
Texas
- Diabetes & Glandular Disease Research Assoc PA - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00662857
The ClinicalTrials.gov registry entry for NCT00662857 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (98% lower). The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 3 interventions - of which Technosphere® Insulin Inhalation Powder is the first listed.
NCT00662857 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT00662857 about?
NCT00662857 is a clinical study titled "A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro". 28 subjects to be enrolled for a screening period, 3 dosing visits \& a follow-up visit. Visits 2 and 3 dosing of TI Inhalation Powder, cross over between two 15 U cartridges and one 30 U cartridge. Visit 4 dosing will be a sc injection of 10 IU of RAA (rapid-acting insulin analogue).
What is the current status of trial NCT00662857?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2008-04. Estimated completion is 2008-12.
What conditions does trial NCT00662857 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT00662857?
The interventions under investigation include: Technosphere® Insulin Inhalation Powder (DRUG), Technosphere Insulin® Inhalation Powder (DRUG), RAA Population (DRUG).
Who is sponsoring clinical trial NCT00662857?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00662857 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Islet Transplantation in Type 1 Diabetic Kidney Allograft
RECRUITING · Phase 2
-
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes
RECRUITING · Phase 2
-
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
ACTIVE NOT RECRUITING · Phase 2
-
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
ACTIVE NOT RECRUITING · Phase 2
-
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
ACTIVE NOT RECRUITING · Phase 2
-
Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.